Exploring the Association Between Atypical Neuroleptic Agents and Diabetes Mellitus in Older Adults

Pharmacotherapy

Volumn 23, Issue 11, 2003, Pages 1411-1415

  Etminan, Mahyar ^a   Streiner, David L ^b   Rochon, Paula A ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMAZEPAM; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CHLORPROTHIXENE; CLORAZEPATE; CLOZAPINE; CORTICOSTEROID; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIAZIDE DIURETIC AGENT; THIORIDAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZUCLOPENTHIXOL;

AGED; ARTICLE; CANADA; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG EXPOSURE; FEMALE; HUMAN; IATROGENIC DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SOCIAL STATUS;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 0142183352     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.14.1411.31939     Document Type: Article

References (26)

1. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990;40:222-47.
2. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-11.
3. Chan WC, Larn LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomized comparison of risperidone and haloperidol in the treatment of behavioral and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156-62.
4. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;22:53:946-55.
5. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998;59:687-8.
6. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999;22:1002-3.
7. Ober SK, Hudak R, Rusterhohz A. Hyperglycemia and olanzapine [letter]. Am J Psychiatry 1999;156:970.
8. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;320:243-8.
9. Rochon PA, Anderson GM, Tu JV, et al. Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario. Can Med Assoc J 1999;161:1403-8.
10. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 2000;356:639-44.
11. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002;17:717-20.
12. Popli AP, Konicki PE, Jurjus GJ, Fuller, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-11.
13. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1988;44:778-83.
14. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary symdromes. JAMA 2002;288:462-7.
15. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.
16. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 2000;342:905-12.
17. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983;32:106-11.
18. Jallon P, Picard F. Body weight gain and anticonvulsants: a comparative review. Drug Safety 2001;24:969-78.
19. Allison PD. Estimating Cox-regression models with PROC PHREG. In: Survival analysis using the SAS system. Cary, NC: SAS Institute, 2000:111-84.
20. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002;22:236-43.
21. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169:483-8.
22. Moride Y, Abenhaim L. Evidence of the depletion of susceptible effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47:731-7.
23. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2000; 11:25-32.
24. Brambilla F, Gustulla G, Guerrini A. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976; 37:98-103.
25. Barak Y. No weight gain among elderly schizophrenia patients after one year of risperidone treatment. J Clin Psychiatry. 2002;63:117-19.
26. Irizarry MC, Ghaemi SN, Lee-Cherry ER, et al. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci 1999;11:336-42.